|
|
Vaccine Detail
|
Racotumomab Vaccine |
| Vaccine Information |
- Vaccine Ontology ID: VO_0007083
- Type: Subunit vaccine
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- KRAS
gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
- NRAS
gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
- HRAS
gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
- Preparation: Racotumomab is adjuvanted with aluminum hydroxide for intradermal administration as a cancer vaccine (Gajdosik, 2014).
- Description: This is for Lung Cancer (NCT01598454). An anti-idiotype murine monoclonal antibody (MoAb) specific to P3 MoAb with anti-metastatic effect. Racotumomab binds to the idiotype region of P3 MoAb and functionally mimics the three-dimensional structure of N-glycolyl ceramides of mono-sialyl lactose, the antigenic target of P3. As a result, this anti-idiotype antibody may stimulate the host immune system to elicit humoral and cellular immune responses against tumor cells expressing NeuGc-GM3 gangliosides, which are expressed in a wide variety of tumor cells (Gabri et al., 2016; NCIT_C95024).
|
| Host Response |
|
|
| References |
Gabri et al., 2016: Gabri MR, Cacciavillano W, Chantada GL, Alonso DF. Racotumomab for treating lung cancer and pediatric refractory malignancies. Expert opinion on biological therapy. 2016; 16(4); 573-578. [PubMed: 26903265].
Gajdosik, 2014: Gajdosik Z. Racotumomab - a novel anti-idiotype monoclonal antibody vaccine for the treatment of cancer. Drugs of today (Barcelona, Spain : 1998). 2014; 50(4); 301-307. [PubMed: 24918647].
NCIT_C95024: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C95024]
NCT01598454: [https://clinicaltrials.gov/ct2/show/NCT01598454]
|
|
